Trump Administration to Launch TrumpRx Drug‑Discount Website as Federal Facilitator to Drugmaker Sites
President Trump will announce TrumpRx at 7 p.m. EST on Thursday, Feb. 5, 2026. The site will act as a federal facilitator that points consumers to drugmakers’ own direct‑to‑consumer websites rather than processing purchases itself; its rollout has been delayed twice, is tied to more than 15 “most favored nations” pricing deals with major drugmakers, and it remains unclear whether the cash prices shown will routinely undercut what insured patients pay through their plans.
📌 Key Facts
- President Trump will announce TrumpRx at 7 p.m. EST on Thursday, Feb. 5, 2026.
- TrumpRx will not directly process purchases; it will act as a federal facilitator that directs consumers to drugmakers’ own direct‑to‑consumer websites.
- The TrumpRx unveiling has been delayed at least twice — once after Dr. Mehmet Oz said the site would show prices before the end of 2025, and again when a planned late‑January launch slipped.
- The Trump administration says it has struck more than 15 'most favored nations' pricing deals with major pharmaceutical companies, and TrumpRx is tied to those agreements.
- There is uncertainty about whether TrumpRx cash prices will routinely be lower than what insured patients already pay through their health plans.
📰 Source Timeline (2)
Follow how coverage of this story developed over time
February 05, 2026
10:49 PM
WATCH LIVE: Trump expected to announce launch of TrumpRx prescription drug site
New information:
- Confirms the launch timing: President Trump will announce TrumpRx at 7 p.m. EST on Thursday, Feb. 5, 2026.
- Specifies that TrumpRx will not directly process purchases but will point consumers to drugmakers’ own direct-to-consumer websites.
- Adds that TrumpRx’s unveiling has been delayed at least twice, once after Dr. Mehmet Oz said the site would show prices before the end of 2025 and again after a planned late-January launch slipped.
- Notes that Trump administration has struck more than 15 'most favored nations' pricing deals with major pharmaceutical companies, tying TrumpRx to those agreements.
- Raises uncertainty about whether TrumpRx cash prices will routinely beat what insured patients already pay through their health plans.